Gynecologic Cancer Survivors: A Study Of Lifestyle Factors Overview Promoting positive outcomes for gynecologic cancer survivors hinges on upholding a healthy lifestyle. We scrutinized behaviors among gynecologic cancer survivors (n = 1824) and non-cancer individuals via cross-sectional analysis, using 2020 Behavioral Risk Factor Surveillance System data. Colorectal cancer screening rates were 7.9%
Oncology
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk The number of non-Hodgkin lymphoma (NHL) cases is rising, with an estimated 81,560 new diagnoses in the US in 2021. As survival rates improve, more NHL survivors face potential late effects, including secondary malignancies (SM) linked to treatments like chemotherapy and radiation. This research revisits
Eosinophilic Dermatosis In Hematological Malignancy (EDHM): Case Study Reports
Eosinophilic Dermatosis In Malignancy (EDHM): Case Study Reports Overview Patients with hematological malignancies may develop various skin eruptions, and one such condition is eosinophilic dermatosis of hematological malignancy (EDHM), also known as an 'insect bite-like' reaction. While cutaneous reactions are not uncommon in hematological malignancies, EDHM is a relatively rare condition that
Uterine Leiomyosarcoma: A Meta-Analysis Of Systemic Therapy Effectiveness
Uterine Leiomyosarcoma: Systemic Therapy Effectiveness Overview Uterine leiomyosarcoma (uLMS) is an aggressive type of mesenchymal tumor linked to a bleak prognosis. The primary treatment for advanced uLMS is systemic chemotherapy, although the most effective regimen remains uncertain. To address this, we conducted an extensive analysis, including both meta-analysis and metaregression, aiming to
Off-label Medication Use In Oncology
Off-label Medication Use In Oncology Cancer Research and Medicinal Drugs Cancer research and innovation are highly active, resulting in the introduction of new medications into the therapeutic arsenal. However, incorporating these new drugs into clinical practice is a challenging and time-consuming process due to regulatory requirements. Before a drug can be marketed and
Monocytosis And Patient Risk Of Malignancy And Mortality
Monocytosis And Patient Risk Of Malignancy And Mortality Monocytosis is a common occurrence in primary care, but its significance is not always clear. In adults, monocytosis is defined as having a higher-than-normal count of monocytes (a type of white blood cell) in the peripheral blood, specifically above 0.8 x 10^9/L. Monocytosis
Bedside Pediatric Early Warning System: A Validation Study
Bedside Pediatric Early Warning System: A Validation Study Overview Conducted in an 80-bed pediatric oncology specialty hospital in the Netherlands, this research was initiated to evaluate the predictive utility of the adapted Bedside Pediatric Early Warning System (BedsidePEWS) score. This study aimed to explore the correlation of this score with unanticipated transfers
Massage Therapy For Oncology Patient Pain
Massage Therapy For Oncology Patient Pain Overview This study aimed to investigate the impact of massage therapy (MT) as a nonpharmacologic approach for addressing various symptoms experienced by children, adolescents, and young adults with hematologic and/or oncologic conditions. The researchers focused on two patient groups: those with sickle cell disease (SCD) and
Eyelid Rhabdomyosarcoma Survival In Children’s Oncology
Eyelid Rhabdomyosarcoma Survival In Children's Oncology Overview Survival outcomes in Orbital Rhabdomyosarcoma (ORMS) typically show excellent results, especially in low-risk cases (stage 1, group I-III, embryonal RMS). However, long-term follow-up data on low-risk ORMS and less common subgroups treated in recent Children's Oncology Group (COG) trials were previously unreported. To fill this
Acute Myeloid Leukemia And Diverse Patient Survival Outcomes
Acute Myeloid Leukemia And Diverse Patient Survival Outcomes Background Cancer remains a prominent global health concern, accounting for a significant number of cases and fatalities worldwide in 2020, with projections indicating further increases in both incidence and mortality rates, particularly in the United States. Hematologic malignancies (HMs) constitute a substantial subset of
